Zomedica Pharmaceuticals Corp (ZOM) — Cash Flow-to-Debt Ratio
Zomedica Pharmaceuticals Corp (ZOM) has a Cash Flow-to-Debt Ratio of -0.63x as of March 2025, meaning its operating cash flow of $-6.65 Million could theoretically repay -1% of its total liabilities ($10.55 Million) in one year. Explore ZOM long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zomedica Pharmaceuticals Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Zomedica Pharmaceuticals Corp across 12 annual periods. Also explore Zomedica Pharmaceuticals Corp balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Zomedica Pharmaceuticals Corp (2013–2024)
Year-by-year debt coverage analysis for Zomedica Pharmaceuticals Corp. For market capitalisation and broader financial context, see Zomedica Pharmaceuticals Corp market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.02x | $-23.63 Million | $11.70 Million | ▼ -66.7% |
| 2023 | -1.21x | $-15.97 Million | $13.18 Million | ▼ -26.9% |
| 2022 | -0.96x | $-11.67 Million | $12.22 Million | ▲ +36.3% |
| 2021 | -1.50x | $-14.28 Million | $9.51 Million | ▼ -39.3% |
| 2020 | -1.08x | $-16.24 Million | $15.08 Million | ▲ +85.6% |
| 2019 | -7.49x | $-15.63 Million | $2.09 Million | ▼ -59.7% |
| 2018 | -4.69x | $-11.15 Million | $2.38 Million | ▲ +45.2% |
| 2017 | -8.56x | $-7.09 Million | $828.74K | ▼ -39.0% |
| 2016 | -6.16x | $-4.56 Million | $741.16K | ▼ -1705.1% |
| 2015 | -0.34x | $-49.88K | $146.29K | ▲ +96.8% |
| 2014 | -10.54x | $-41.44K | $3.93K | ▲ +12.6% |
| 2013 | -12.06x | $-62.19K | $5.16K | — |